AI English summary of an SEC filing — figures as filed

The company said Silji Abraham, Senior Vice President & Chief Technology Officer, notified it on October 1, 2024 that he is resigning, with the resignation effective December 31, 2024.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Oct 7, 2024Period of report Oct 1, 2024Summary published (UTC) Oct 25, 2026

Key points

AI summary

The company said Silji Abraham, Senior Vice President & Chief Technology Officer, notified it on October 1, 2024 that he is resigning, with the resignation effective December 31, 2024.
West Pharmaceutical said Mr. Abraham notified the company that he intends to resign to pursue other interests.
The company said Mr. Abraham's departure is not the result of any disagreement with the company on matters related to operations, policies or practices, and that he will receive no additional compensation as a result of his departure.
The company said it will work with Mr. Abraham and his leadership team to ensure a smooth transition of his duties before his departure.

Summary

AI-written

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Silji Abraham gives notice of resignation on October 1, 2024

The company said Silji Abraham, Senior Vice President & Chief Technology Officer, notified it on October 1, 2024 that he is resigning, with the resignation effective December 31, 2024.

Source · Based on the filing body and exhibits

Reason for resignation: to pursue other interests

West Pharmaceutical said Mr. Abraham notified the company that he intends to resign to pursue other interests.

Source · Based on the filing body and exhibits

No disagreement on operations, policies or practices

The company said Mr. Abraham's departure is not the result of any disagreement with the company on matters related to operations, policies or practices, and that he will receive no additional compensation as a result of his departure.

Source · Based on the filing body and exhibits

Plan for smooth transition of duties

The company said it will work with Mr. Abraham and his leadership team to ensure a smooth transition of his duties before his departure.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.